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The bone metastasis niche in breast cancer-potential overlap with the
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A B S T R A C T
Background: Bone metastasis is one of the most common complications of advanced breast cancer. During
dissemination to bone, breast cancer cells locate in a putative ‘metastatic niche’, a microenvironment that
regulates the colonisation, maintenance of tumour cell dormancy and subsequent tumour growth. The precise
location and composition of the bone metastatic niche is not clearly deined. We have used in vivo models of early
breast cancer dissemination to provide novel evidence that demonstrates overlap between endosteal, perivas-
cular, HSC and the metastatic niche in bone.
Methods: Estrogen Receptor (ER) +ve and -ve breast cancer cells were labelled with membrane dyes Vybrant-
DiD and Vybrant-CM-DiI and injected via diferent routes in BALBc/nude mice of diferent ages. Two-photon
microscopy was used to detect and quantitate tumour cells and map their location within the bone micro-
environment as well as their distance to the nearest bone surface compared to the nearest other tumour cell. To
investigate whether the metastatic niche overlapped with the HSC niche, animals were pre-treated with the
CXCR4 antagonist AMD3100 to mobilise hematopoietic (HSCs) prior to injection of breast cancer cells.
Results: Breast cancer cells displayed a characteristic pattern of homing in the long bones, with the majority
of tumour cells seeded in the trabecular regions, regardless of the route of injection, cell-line characteristics (ER
status) or animal age. Breast cancer cells located in close proximity to the nearest bone surface and the average
distance between individual tumour cells was higher than their distance to bone. Mobilisation of HSCs from the
niche to the circulation prior to injection of cell lines resulted in increased numbers of tumour cells disseminated
in trabecular regions.
Conclusion: Our data provide evidence that homing of breast cancer cells is independent of their ER status
and that the breast cancer bone metastasis niche is located within the trabecular region of bone, an area rich in
osteoblasts and microvessels. The increased number of breast cancer cells homing to bone after mobilisation of
HSCs suggests that the HSC and the bone metastasis niche overlap.
1. Introduction
Metastatic breast cancer remains a major cause of female cancer-
related deaths, despite the improvements in early detection and therapy
introduced over the past decades [1,2]. The most frequent metastatic
site is the skeleton, but other distant organs including brain, lungs and
liver are also afected [3]. Secondary disease, particularly skeletal
metastasis, can develop decades after the detection and treatment of the
primary tumour. Recent studies show that the risk of distant recurrence
increases at a steady rate for at least 20 years [4]. Bone metastases are
associated with major complications such as hypercalcaemia, patholo-
gical fractures and spinal cord compression, resulting in a considerable
reduction in quality of life [5]. Although the focus of intensive research,
the mechanisms initiating the metastatic process are not fully under-
stood [6], and the lack of available patient bone biopsies containing
tumour cells hampers the investigation of bone metastasis in humans.
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Therefore, pre-clinical models are extensively used to investigate the
mechanisms underpinning metastatic spread, including to the skeleton,
in order to identify potential therapeutic targets.
The development of metastasis in distant organs is a multistep
process that begins with the detachment of cancer cells from the pri-
mary tumour, via their invasion of the extra-cellular matrix, entry into
the blood stream and the eventual colonisation and outgrowth at sec-
ondary sites [3,7,8]. However, only a small proportion of the cells that
escape from the primary tumour will successfully colonise a distant
organ, with the majority of circulating tumour cells (CTCs) being re-
cognised and eliminated by the immune system, undergoing sponta-
neous apoptosis or re-entering the blood stream and potentially colo-
nising other organ(s) [9–12]. Once the CTCs have colonised the bone
microenvironment, they are referred to as disseminated tumour cells
(DTCs), for which there are several diferent fates: (1) death by spon-
taneous apoptosis or elimination by the host immune system; (2) return
to the circulation; (3) entry into a quiescent or dormant state; and (4)
proliferation with induction of cancer-induced bone disease [7,9–12]. It
is hypothesised that DTCs, particular those derived from prostate and
breast cancers, colonise specialized regions of bone microenvironment
in which they can be held in a quiescent state; ‘The Metastatic Niche(s)’
[3]. This bone region is characterized by a complex milieu of cytokines,
hormones and soluble factors produced by the diferent components of
the surrounding niches, creating a rich soil for seeding of the tumour
cells. This metastatic niche strongly inluences the fate of DTCs arriving
in bone, driving them towards either dormancy or proliferation and
development of overt bone metastases [13]. The precise position and
composition of the metastatic niche has not yet been established, but
studies from murine model systems have provided evidence that tu-
mour cells locate in regions of bone where the HSC niche, endosteal
niche and perivascular niche overlap [14–17]. Cells of the osteoblastic
lineage are reported to be involved in the tumour establishment and
progression of bone metastases in pre-clinical models of both breast and
prostate cancer [18,19]. In addition, Shiozawa et al. elegantly showed
how prostate cancer cells and HSCs locate within the same niche
[20,21], supporting the hypothesis of an overlap between niches in
bone. The HSC niche is found in close proximity to the endosteal surface
of the trabecular bone, an area that is highly vascularised [17,22–25].
Whilst the contribution of the vasculature in the early stage of bone
metastasis is not fully elucidated, a recent study has provided some
evidence that the perivascular niche is a key regulator of breast cancer
cell dormancy. Ghajar et al. used a range of in vitro model systems to
demonstrate that breast cancer cells associated with a quiescent mi-
crovasculature promotes tumour cell dormancy, whereas this is re-
versed during vessel sprouting [26]. It is a well-established concept that
the microenvironment plays an important role in all the stages of bone
metastasis, however the precise cellular composition of the metastatic
niche remains to be deined.
To date, most studies of bone metastasis have focused on advanced
stages of cancer-induced disease, where the micro- or macro-metastases
are already established. In contrast, much less information is available
regarding the early stages of breast cancer bone colonisation, when
tumour cells remain in a dormant state within the bone marrow. There
are several key questions that remain to be addressed. Do cancer cells
compete with each other, or with other bone-residing cell populations,
for access to a limited number of suitable niches that could become
saturated? We also do not know the fate of tumour cells that arrive in
bone to ind that the prime niches are occupied. The application of
novel technologies, such as two-photon microscopy and the use of li-
pophilic dyes that are retained in non-proliferating (tumour) cells, has
facilitated studies of the initial stages of the metastatic process in model
systems, as well as how changes in bone cell populations afects the
homing of tumour cells [27,28]. We have combined these approaches to
quantify and map single breast cancer cells of diferent molecular
subtypes within the long bones of mice, determining their precise po-
sition in relation to the calciied structures, the neighbouring tumour
cells and their spatial relationship to key components of the bone mi-
croenvironment. We demonstrate that ER+ve and ER-ve breast cancer
cells display the same homing pattern in bone and that this is in-
dependent of the injection route used or the age of the animal. Finally,
we provide novel evidence that breast cancer cells home to the HSC
niche.
2. Materials and methods
2.1. Tumour cell lines
MDA-MB-231-GFP-IV [29], T47D and MCF7 breast cancer cell lines
(ATCC) were cultured in RPMI 1640 supplemented with 10% FBS (Life
Technologies, Paisley, UK /Invitrogen) at 37 °C 5%CO2, MDA-MB-231-
NW1-Luc2 cells were cultured in DMEM (Life Technologies, Paisley,
UK)+Pyruvate medium enriched with 100 U/mL penicillin/strepto-
mycin and 10% FBS (Sigma Aldrich Co Ltd, Poole, UK). Prior to the
injections, tumour cells were labelled either with the lipophilic mem-
brane dye Vybrant-CM-DiI or Vybrant-DiD (Life Technologies Ltd,
Paisley, UK) according to the manufacturer's instructions.
2.2. Animal models
Six-week old and twelve-week old female BALB/c nude mice
(Charles River, UK) were used to assess the homing of breast cancer
cells in bone and to establish any efects of modiication of the niche.
Mice were housed in a controlled environment with a 12 h light/dark
cycle at 22 °C. They were provided with ad libitum access to 2018
Teklad Global 18% protein rodent diet containing 1.01% Calcium
(Harlan Laboratories, UK) and water, and housed in groups of 5/6 in
ventilated cages. The Research Ethics Committee for animal experi-
mentation, of the University of Sheield, UK reviewed and the Home
Oice approved all the work included in this manuscript. All in vivo
experiments were performed in accordance with the UK Animals
(Scientiic Procedures) Act 1986 Home Oice regulations under the
authority of PPL 70/8964 and PPL 70/8799.
2.3. Bone homing studies
To assess the homing of breast cancer tumour cells to bone, 12-week
old female BALB/c nude mice were injected intravenously (i.v.) with
1×105 MDA-MB-231-GFP-IV breast cancer cells labelled either with
the membrane dye Vybrant-CM-DiI or Vybrant-DiD and culled on day 5.
Hind limbs were dissected, muscles removed, femora and tibiae sepa-
rated and processed for imaging as described below.
To investigate whether diferent routes of administration afected
the pattern of homing of breast cancer cells, 12-week old female BALB/
c nude mice were injected either intravenously (n=1) or via the in-
tracardiac (i.c) route (n=5) with 1× 105 MDA-MB-231-GFP-IV breast
cancer cells labelled with the membrane dye Vybrant-DiD and then
culled on day 5 and long bones collected.
To establish whether the oestrogen receptor (ER) status of the breast
cancer cells afected their pattern of bone homing, 1× 105 Vybrant-DiD
labelled ER-ve MDA-MB-231-GFP-IV cells, ER+ve MCF-7 or T47D cells
were injected i.c. in 12-week old female BALB/c nude mice (n=5/
group). Long bones were collected 5 days after cell injection and pro-
cessed for imaging as described below.
2.4. Modification of the HSC niche
To conirm that AMD3100 mobilises HSC/progenitor cells (PCs)
from bone marrow niches into the circulation, 12-week old female
BALB/c-Nude mice were treated with AMD3100 (5mg/kg, i.p.) or
Saline daily for 5 days. Three hours after the last drug administration,
mice were culled and peripheral blood isolated by cardiac puncture
using syringes containing 4% sodium citrate. Blood was centrifuged to
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remove the serum and red blood cells lysed with ammonium chloride
solution (BioLegend Ltd, UK). Peripheral blood mononuclear cells were
resuspended in IMDM supplemented with 2% FCS and 100 u/mL
Penicillin/Streptomycin at a density of 2×106 cells/mL. Cell suspen-
sions were diluted 1:10 with MethoCult GF 3434 medium (Stem Cell
Technologies), seeded into 6-well plates and maintained in an humi-
diied atmosphere at 37 °C with 5% CO2 for 11 days to allow colony
formation. Bright ield images of colonies were taken using a Leica
DMI4000B microscope.
To assess whether the mobilisation of hematopoietic stem cells
(HSCs) would afect homing of breast cancer cells in bone, 12-week old
female BALB/c nude were injected i.p. with the CXCR4 antagonist
AMD3100 (Sigma-Aldrich) 5mg/kg (100 µl) or PBS daily for 5 days.
24 h after the last injection, animals were injected i.v with 1×105
MDA-MB-231-GFP-IV Vybrant-DiD -labelled cells and culled on day 10.
2.5. Comparison between young and mature animals
To compare the seeding of breast cancer cells in the bone micro-
environment of young and mature animals 6- and 12-week old female
BALB/c nude mice (n=8/group) were injected i.v. with 1×105 MDA-
MB-231-GFP-IV cells labelled with the membrane dye Vybrant-CM-DiI.
Animals were culled 5 days after tumour cell injection.
2.6. µCT analysis
Microcomputed tomography (µCT) analysis was carried out on the
resected long bones ex vivo using a Skyscan 1272 X-ray-computed mi-
crotomograph (Skyscan). Image acquisition was performed using a
voltage of 50 kV, a current of 200 µA, a medium camera resolution of
2016×1344, an aluminium ilter of 0.5 mm and a pixel size of 4.3 µm.
Images were captured of proximal tibias every 0.7° through a 180° ro-
tation. Acquired images were reconstructed and analyzed using NRecon
and CTAn software (Skyscan).
2.7. Two-photon microscopy
Animals were culled, hind limbs dissected, muscles removed, fe-
mora and tibiae separated and collected snap frozen in liquid nitrogen
and stored at −80 °C. Cryopreserved long bones were then embedded
into Cryo-M-Bed (Instrument Co. Ltd, Huntingdon, UK) and the bone
marrow exposed using a Bright OTF Cryostat and a 3020 microtome
(Bright Instrument Co. Ltd, Huntingdon, UK). A stack area of exposed
bone marrow (2104 µm×2525 µm 70 µm depth) was captured using a
Zeiss LSM510 NLO upright 2-photon/confocal microscope (Carl Zeiss
Inl, Cambridge, UK). DiD-labelled and CM-Dil-labelled breast cancer
cells were visualised using a 633 nm HeNe and 543 HeNe lasers, re-
spectively. The bone structure was detected with a Chameleon 2-photon
laser at 900 nm (Coherent, Santa Clara, CA.). The Volocity 3D Image
Analysis software 6.01 (PerkinElmer, Cambridge, UK) was used to
quantify the abundance of Vybrant-CM-DiI or Vybrant-DiD events, their
distance to the nearest bone surface and to other DTCs [27]. The
quantiication of dye-labelled tumour cells and their spatial distribution
were performed in two diferent regions of interest (ROIs, Fig. 2B) from
which the cortical bone was excluded.
2.8. Confocal microscopy
Long bones were ixed in 4%PFA, decalciied in 0.5M EDTA, em-
bedded in gelatin and frozen at −80 °C [27]. Immunoluorescence was
performed on 30 µm thick cryosections (three non-consecutive levels)
for each bone. Tissue sections were permeabilized for 30 min in 0.3%
Triton X-100, where appropriate Streptavidin/Biotin blocking (Vector
Labs) was performed. Cryosections were incubated for 1 h with primary
antibody against murine Endomucin (2 µg/mL, Santa Cruz Bio-
technology), Osteopontin (R&D Systems) or human CD29 and CD59
(10 µg/mL, BioLegend). Tissue sections were washed with PBS and in-
cubated with either a luorescently-conjugated (5 µg/mL) or biotiny-
lated secondary (7.5 µg/mL) antibody followed by luorescently-con-
jugated streptavidin. Tissue sections were washed with PBS and
incubated with either a luorescently-conjugated or biotinylated sec-
ondary antibody followed by luorescently-conjugated streptavidin. All
incubations were carried out at ambient temperature and ProLong Gold
Antifade reagent (Thermo Fisher) to mount the glass coverslips. Images
of the immunoluorescence staining were captured with Nikon A1
(Nikon Instruments Europe) or Zeiss LSM 880 AiryScan (Carl Zeiss
Microscopy GmBH) confocal systems.
2.9. Statistical analysis
Statistical analyses were performed using GraphPad Prism software
(Version 6.0 and 7.0). Student T-tests and Two-way ANOVA and
Tukey's post hoc test were used as indicated in each igure legend. A p-
value of p < 0.05 was considered signiicant.
3. Results
During the metastatic process, breast cancer cells home to a putative
bone metastatic niche. In our in vivo models of bone metastasis, intra-
cardiac injection of Luc2 expressing breast cancer cells results in the
majority of tumours developing in the highly vascularised metaphysis
region of the long bones (Fig. 1). To deine the location of the meta-
static niche in our model, we therefore analysed the tibiae and femora
to assess the location of breast cancer cells during the early stages (<10
days after tumour cell injection as deined by our previously published
Fig. 1. In vivo tumour model and location of the bone metastatic niche. (A)
Representative image of the breast cancer bone metastasis animal model.
Female BALB/c nude mice were injected i.c. MDA-MB-231-GFP cells transfected
with luciferase, tumour growth was detected in the hind limbs using an in vivo
imaging system (IVIS). (B) Representative micro-computed tomography re-
construction illustrating the trabecular architecture of the tibia. (C)
Immunoluorescence staining using antibody against the endothelial marker
endomucin to visualise the extensive microvascular network of long bones. (D)
Immunoluorescence staining of a tumour bearing tibial section using an anti-
body speciic for the endothelial cell marker endomucin. Dotted yellow
line= tumour outline, BM=bone marrow, GP=growth plate,
green=Endomucin and blue=DAPI, scale bar= 200um. (For interpretation
of the references to color in this igure legend, the reader is referred to the web
version of this article.)
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studies of bone colonisation [30].
3.1. MDA-MB-231-GFP-IV bone seeking cells preferentially home to the
trabecular region of bone
In previous studies we have demonstrated that the bone seeking
MDA-MB-231-IV cells form detectable tumours in long bones two weeks
after injection into the tail vein of 6-week old animals, in which tumour
growth is supported by active bone turnover [29]. The aim of the
current study was to investigate tumour cell dissemination in the ab-
sence of growing colonies. We therefore used 12-week old animals, in
which we have shown that low levels of bone turnover supports DTC
dormancy rather than outgrowth [31]. Animals were culled 5 days after
tumour cell injection, allowing DTCs to home to bone, but without
starting to proliferate resulting in loss of the luorescent membrane
label. Moreover, at this time point, DTCs that have not reach a sup-
portive niche will have undergone apoptosis and been cleared from the
bone marrow, allowing quantiication of the DTCs in bone that contain
the metastasis-initiating population.
To investigate whether breast cancer cells have a preferential pat-
tern of homing within the long bones, 12-week old mice were injected
with bone-seeking MDA-MB-231-IV breast cancer cells labelled with
either Vybrant-CM-DiI (Fig. 2C, E) or Vybrant-DID (Fig. 2D, F) and the
number of events located in two diferent regions of interested (ROIs)
were quantiied by two-photon microscopy. The regions of interest
encompassed either the trabecular bone (ROI1) and the area im-
mediately adjacent to the growth plate (ROI2), one luorescent event
detected is equivalent to one tumour cell (Fig. 2B).
MDA-MB-231-GFP-IV cells localised preferentially in the trabecular
region of the bone marrow (ROI1) rather than in the growth plate area
(ROI2). Irrespective of the dye used to label the cells, the events/mm3
recorded in ROI1 were signiicantly higher compared to those in ROI2
(Vybrant-CM-DiI labelled cells p=0.0047 and Vybrant-DiD labelled
cells p < 0.0001) (Fig. 2E and F). Although the overall number of with
Vybrant-CM-DiI+ events was lower when compared to Vybrant-DiD+
events, the homing pattern was comparable irrespective of the label
used. These results demonstrate that in this in vivo model of low bone
turnover, disseminated breast cancer cells mainly locate to the trabe-
cular region of the metaphysis.
3.2. MDA-MB-231-GFP-IV cells locate close to the bone surface
Tumour cells interact with the various components of the bone
metastatic niche to develop into overt metastases, in particular with the
bone-forming (osteoblasts) and the bone-resorbing (osteoclasts) cells
[32]. In order to determine the precise location of MDA-MB-231-IV cells
within the microenvironment, we measured the distance from the edge
of each tumour cell to the nearest bone surface (covered with osteo-
blasts). In order to determine whether DTCs tended to co-locate in the
same niche and/or form small clusters, the distance to the closest other
DTC was also measured. The distances were obtained using Volocity 3D
Image Analysis software as illustrated in Fig. 3A and B. In ROI1, the
mean distance between Vybrant-CM-Dil labelled tumour cells and the
nearest bone surface was 71.90 ± 11.82 µm (range 23–144 µm), for
Vybrant-DiD cells was 108.27 ± 42.19µm (63–192 µm) whilst the
overall mean was 79.70 ± 12.66 µm. Compared to ROI1, Vybrant-CM-
DiI labelled cells were located signiicantly (p=0.0373) closer to the
bone surface in ROI2 where the mean distance was 24.93 ± 4.85µm
(Fig. 3C). In contrast in ROI2, the distance between individual tumour
cells was signiicantly greater, 384.30 ± 129.80 µm in the growth
plate area compared to the trabecular bone region, with mean values of
174.9 ± 26.07 µm (p=0.0239) (Fig. 3D). In both ROIs, the bone-
seeking cell-line MDA-MB-231-GFP-IV homed signiicantly closer to the
nearest bone surface than to the nearest tumour cell (p=0.0015 in
ROI1 and p=0.0214 in ROI2, Fig. 3E and 3F). Taken together, our data
show that DTCs home to niches in close proximity to the nearest bone
surface and that tumour cells are not found to cluster together.
3.3. MDA-MB-231-GFP-IV cells homing to bone is not affected by the route
of administration
Due to their characteristic bone tropism, MDA-MB-231-GFP-IV cells
home to the long bones following tail vein injection [29]. In contrast,
most xenograft models of bone metastasis involve administration of
tumour cells via the intracardiac route, allowing the cells to reach the
bone through the arterial circulation. To determine whether the route
of injection modiies the initial stages of breast cancer cell bone colo-
nisation, 12-week old BALB/c nude mice were injected with MDA-MB-
231-GFP-IV Vybrant-DiD labelled cells either i.v. (n=1, to conirm the
pattern described above) or i.c. (n=5) and after 5 days long bones
were collected and tumour cells were visualized in the bone micro-
environment and quantiied using two-photon microscopy (Fig. 4).
When injected via the tail vein, MDA-MB-231-GFP-IV cells dis-
played the same pattern of homing as described above (ROI1>ROI2),
but did not show signiicant diferences between events recorded in the
trabecular region of the bone compared to the growth plate area
(p=0.4480) (Fig. 4B). This was probably due to the limited number of
samples available for analysis.
When injected via the intracardiac route, the majority of MDA-MB-
231-GFP-IV cells still located in ROI1 compared to ROI2 (p=0.0464)
(Fig. 4B). Moreover, the tumour cells colonised areas in close proximity
to the bone surface with a mean value of 56.99± 11.55µm in ROI1 and
10.30±4.04µm in ROI2 (p=0.0053). As was observed following i.v.
injection, the distance to the nearest other tumour cell was higher than
that to the nearest bone surface, mean value of 253.50±110.40µm in
ROI1 and 174.90± 53.36µm in ROI2 (p=0.1225 and p=0.0096 in
ROI1 and ROI2 respectively) (Fig. 4C).
Taken together, these results show tumour cells capable of meta-
static outgrowth home to trabecular bone irrespective of their route of
injection and conirm that triple negative breast cancer cells generally
seed in the trabecular region of the metaphysis in close proximity to the
bone surface.
3.4. ER+ve breast cancer cell-lines exhibit the same pattern of seeding as
triple negative cell-lines
The majority of breast cancers are ER +ve, and bone metastasis is
more commonly seen in patients with ER+ve tumours. In contrast,
most in vivo models of bone metastasis use triple negative breast cancer
cell-lines (e.g. MDA-MB-231). We next investigated whether ER+ve
breast cancer cells colonised bone in the same way as ER-ve breast
cancer cells. For these experiments, the ER+ve cell lines T47D and
MCF-7 were labelled with Vybrant-DiD and injected into 12-week old
mice via the intra cardiac route (Fig. 5A).
Similar to the triple negative breast cancer cell-lines, the ER+ve
cell-lines also displayed a trend towards homing to the trabecular re-
gion of the bone compared to the area adjacent to the growth plate,
although the p-value did not reach statistical signiicance (p=0.3481
for T47D and p=0.2457 for MCF7 cell-line, Fig. 5B-D). Interestingly,
the number of T47D cells reaching the bone microenvironment (ROI1)
was lower than for the MCF7 cells, (p=0.0472) (Fig. 5B).
MCF7 cells appeared to home slightly further from the bone surface
in ROI1 compared to all the other cell-lines analysed, with a mean value
of 118.50 ± 48.44 µm (42–257 µm) while in ROI2 the mean distance
of 6.09 ± 2.21 µm (0–10 µm) is comparable to both the triple negative
cell-line and the ER+ve clone T47D (Fig. 5C).
Of all the cell-lines investigated, T47D cells were in closest proxi-
mity to the bone surface, with a mean distance of 27 µm (0–71 µm) to
the nearest bone surface in ROI1, suggestive of breast cancer cell sub-
type speciic diferences in niche location (Fig. 5C). These results con-
irm that both ER+ve and ER-ve breast cancer cells colonise the same
region of the bone microenvironment.
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3.5. Breast cancer cells colonise the same areas of bone in both young and
mature mice
We have previously shown that young mice (<6-week old) develop
bone metastases with higher frequency when compared to mature
(>12-week old) mice following tumour cell administration, and that
this is associated with diferences in bone turnover which is higher in
young compared to mature animals [30,31]. To establish if this is due to
a diference in the number of breast cancer cells reaching the bone
microenvironment in mice of diferent ages, 1× 105 MDA-MB-231-
GFP-IV cells labelled with Vybrant-CM-DiI were injected i.v. into 6- and
12-week old BALB/c nude mice (Fig. 6). Five days after injection the
animals were culled and long bones were collected for two-photon
microscopy (femora) and for micro-computed tomography (μCT) and
luorescent immunohistochemistry (tibiae). Analyses were performed in
tumour-cell bearing bones only (n=5 for 6-week old and n=11 for
12-week old mice). There was a marked diference in the bone archi-
tecture of the metaphysis between young and mature animals as illu-
strated by representative images in Fig. 6B. The µCT analysis revealed
that although there was no diference in the trabecular bone volume
Fig. 2. Homing of the bone-seeking MDA-MB-231-GFP-IV cell-line. (A) Experimental outline of the in vivo study. 12-week old female BALB/c nude mice were injected
intravenously (i.v.) with PBS on day 0 followed by 1×105MDA-MB-231-GFP-IV cells labelled with Vybrant-CM-DiI (n=6) or Vybrant-DiI (n=2) on day 7. Animals
were culled on day 12 and tibiae and femora were collected for analysis by two-photon microscopy. (B) Schematic representation of the regions of interest (ROIs) of
two-photon bone scan analysed: ROI1 consists of the trabecular bone region and ROI2 of the area of bone immediately adjacent to/including the growth plate.
Cortical bone was excluded. (C) and (D) are examples of two-photon scan showing bone (white), Vybrant-CM-DiI+cells (blue and blue arrows in panel C) and
Vybrant-DID+cells (red and red arrows in panel D). Scale bars 100 µm.(E) and (F) Show the number of Vybrant-CM-DiI+ events/mm3 (n=11 bones analysed),
Vybrant-DiD+(n=3 bones analysed) events. **p≤0.005 and ****p<0.0001 student's t-test, graphs show mean±SEM. (For interpretation of the references to
color in this igure legend, the reader is referred to the web version of this article.)
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between the two diferent age groups (p=0.1023), there was a sig-
niicant diference in both the number and thickness of the trabeculae.
The trabeculae of young animals were signiicantly thinner
(p<0.0001) and their number was signiicantly higher (p=0.0034)
when compared with mature animals, demonstrating that the area of
bone containing/comprising the metastatic niche is altered with age
(Supplementary Fig. 1).
The preferential homing pattern of breast cancer cells was main-
tained, with fewer DTCs detected in ROI2 compared to ROI1, although
this did not reach statistical signiicance in the young animals
(p=0.0960 for 6-week old and p=0.0047 for 12-week old animals)
(Fig. 6C and D). Moreover, despite the identiied diferences in bone
architecture, there were no signiicant diferences in the average
number of breast cancer cells located in ROI1 (44.91 ± 12.46 in 6-
week old and 56.64 ± 11.05 in 12-week old, p=0.5372) and ROI2
(14.60 ± 10.15 in 6-week old and 16.83 ± 5.91 in 12-week old,
p=0.8430) between the diferent age groups (Fig. 6E and F).
Irrespective of age, breast cancer cells located close to the bone
surface in the trabecular region, with a mean value of 30.49 ± 6.92 µm
(13–52 µm range) in 6-week old and 49.97 ± 11.55 µm (10–143 µm
range) in 12-week old mice. Breast cancer cells preferentially home
signiicantly closer to the bone surface than to other tumour cells
(174.40 ± 31.94 µm, p = 0.0064 in 6-week old and
155.80 ± 30.49µm, p = 0.0047 in 12-week old) (Fig. 6G). Distances
were not measured in ROI2 due to the low number of bones in which
tumour cells were detected in this region.
Taken together, these results conirm that the pattern of breast
cancer bone colonisation is independent of animal age, with a sig-
niicantly higher number of events, closer proximity to the nearest bone
surface and a signiicantly higher distance to the nearest tumour cell, in
ROI1 compared to ROI2.
3.6. Modification of the HSCs niche changes the homing of breast cancer
cells
It has been suggested that the metastatic niche broadly overlaps
Fig. 3. Location of MDA-MB-231-GFP-IV cells in the bone microenvironment. (A) Schematic illustration of the distances measured from the edge of the tumour cells
to the nearest bone surface and (B) to the closest other cancer cell. Graphs show the distance of Vybrant-CM-DiI cells to the bone surface (C) and to other tumour cells
(D) (n=11 bones analysed). The comparison between the distances to the bone surface and to other tumour cells in ROI1 is shown in (E) and in ROI2 in (F).
*p≤0.05 and **p≤0.01, student's t-test, graphs show mean±SEM.
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with the hematopoietic stem cell niche in the trabecular region of the
metaphysis of long bones. Shiozawa et al. elegantly demonstrated that
prostate cancer cells and HSCs locate within the same niche [20,21]
using a CXCR4 antagonist (AMD3100) to mobilize the HSCs, but it is
not known whether this is also the case for breast cancer cells. We
therefore used a similar approach to investigate whether mobilisation
of HSCs from the bone niche into the circulation would increase the
number of sites available for tumour cells to colonise, as outlined in
Fig. 7A. To allow direct comparison with the Shiozawa study, the same
dose of AMD3100 (5mg/kg i.p) shown in their study to mobilise HSCs
[20] was injected daily for 5 days in 12-week old mice. As shown in
Fig. 7B, after 11 days of culture ex vivo there was a signiicant increase
in colony numbers generated from HSC/and other progenitor cells
(PCs) isolated from blood samples of AMD3100-treated mice compared
to control, demonstrating successful mobilization of HSCs/PCs. Next,
Vybrant-CM-DiI labelled MDA-MB-231-GFP-IV cells were injected into
the tail vein of animals that had received 5 days of AMD3100 or control
treatment. Animals were culled 5 days following tumour cell injection
and the number and location of tumour cells in the bone marrow was
compared between control and AMD3100 treated animals using two-
photon microscopy.
There was a signiicantly greater number of tumour cells colonizing
the trabecular region (ROI1) of the bone in AMD3100 treated mice
compared to control (p = 0.0409). In contrast, no diference in tumour
cell number was observed in the growth plate area of the bone
(p=0.7303), which is usually less colonised and does not contain HSCs
niches (Fig. 7B). Alteration of the HSCs population resulted in a mod-
iication of the number of tumour cells locating to bone niches, sup-
porting that breast cancer cells home to HSC niches when arriving in
bone.
3.7. DTC in bone marrow locate adjacent to components of the perivascular
niche
The exact composition of the metastatic niche has not yet been
elucidated, but tumour cells are reported to locate in regions of bone
where the HSCs, endosteal and perivascular niches overlap [14–17].
The perivascular niche in particular has been suggested to inluence the
fate of DTC by modulation of the expression of Thrombospondin-1
(supporting dormancy) and TGF-β1 and periostin (promoting tumour
growth). To investigate the spatial relationship between breast cancer
cells, endosteal surfaces and bone microvessels, 30 µm thick tibial
sections of long bones, isolated from 6-week and 12-week old animals 6
days following tumour cell injection, were stained with antibodies
against endomucin (a pan-endothelial marker to visualise the entire
capillary network), the bone marker osteopontin and human CD29 and
CD59 (markers expressed on the human tumour cells). As shown in
Fig. 8, the tumour cells (red) were found outside vessels but im-
mediately adjacent to endothelial cells (green, left hand panels), closely
associated with bone (white, right hand panels). Our data are in
agreement with tumour cells locating to in the perivascular niche at this
time point. Future studies will include quantiication of DTCs in rela-
tion to the diferent vessel subtypes.
4. Discussion
Bone metastasis remains a major clinical challenge in advanced
breast cancer, and is frequently associated with pain, loss of mobility
and in severe cases pathological fractures. Current standard therapies
for established bone metastasis are anti-resorptive agents that act to
slow disease progression and improve quality of life but without
Fig. 4. Comparison between diferent routes of tumour cell injection. (A) Experimental outline of the in vivo study. 12-week old female BALB/c nude mice were
injected either i.v. (n=1) or i.c. with 1× 105 MDA-MB-231-GFP-IV cells labelled with Vybrant-DiD (n=5) to compare the pattern of homing using diferent routes
of injection. (B) Graph representing the direct comparison between the homing of MDA-MB-231-GFP-IV cells after i.v and i.c injection. Comparison between the
distance to the nearest bone surface and to the closest tumour cells after i.c. injection is show in (C). *p≤0.05 and **p≤0.01 student's t-test and two-way ANOVA
and Tukey post-hoc test.
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improving survival [5]. Elucidating the role of the microenvironment in
supporting tumour development and progression is key to improving
cancer therapies, as targeting the tumour cells alone is not suicient to
eradicate disease in the majority of cases [33] In particular, the use of
bone-targeted agents to modify bone marrow niches from a supportive
to a ‘hostile’ environment has been widely investigated, including the
evaluation of anti-resorptive bisphosphonates in large adjuvant trials in
breast cancer [34]. However, there is currently no efective therapy for
general prevention of bone metastasis, thus to develop additional
therapeutic agents with enhanced eicacy, we need a more compre-
hensive understanding of the key interactions that facilitate the early
stages of tumour cell colonisation and survival in bone. Whilst still
impossible in humans, the use of in vivo model systems allows the de-
tection of individual (labelled) tumour cells ex vivo and mapping of
their location and proximity to diferent cell types in bone at diferent
time point. In this study, we have used a combination of murine bone
Fig. 5. Homing of ER+ve cell lines. (A) Experimental outline of the in vivo study. 12-week old female BALB/c nude mice were injected on day 1 with 1×105 T47D
or MCF7 Vybrant-DiD labelled cells i.c. (n=5/group) to compare the homing pattern of ER+ve cell-lines with the triple negative MDA-MB-231. Five days later,
animals were culled and long bones collected for ex-vivo two-photon analysis. (B) Graph representing the direct comparison between the homing of T47D cells vs
MCF7 cells (n=5 bones/group analysed). (C) Comparison between the distances to the nearest bone surface of the two cell-lines injected. *p≤0.05 two-way
ANOVA and Tukey post-hoc test. Examples of two-photon scan showing the proximity to the bone surface of T47D (D) and MCF7 (E), position of the cells is
highlighted by the yellow arrows and scale bar are 100 µm (right panel) and 50 µm (left panel). (For interpretation of the references to color in this igure legend, the
reader is referred to the web version of this article.)
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metastasis models and advanced imaging to determine the early stages
of tumour cell colonisation of bone, comparing ER+ve and ER-ve cells,
diferent injection routes and recipient ages, in addition to evaluating
how pharmacological alteration of the microenvironment modiies
subsequent tumour cell homing.
Despite the large number of breast cancer cells that were
successfully injected into the circulation of our animal models, only a
small portion colonized the long bones of immunocompromised mice.
In the bone metastasis models used in this study, the majority of tumour
cells are eliminated by day 5 due to a combination of factors; cell death
in the circulation, inability to locate an appropriate niche and/or
elimination by innate immune cells. This observation is in agreement
Fig. 6. Homing of MDA-MB-231-GFP-IV cells in young and mature mice. (A) Experimental outline of the in vivo study. 6- and 12-week old female BALB/c nude mice
(n=8/group) were injected on day 1 with 1× 105 CM-DiI labelled MDA-MB-231-GFP-IV cells i.v. Five days later, animals were culled and long bones collected for
ex-vivo two-photon analysis. (B) The number of MDA-MB-231-GFP-IV cells detected in 6- and 12-week old mice 5 days after tumour cell i.v. injection (n=8/group),
graph shows mean±SEM. (C) Distances of the tumour cells to the nearest bone surface and to the closest breast cancer cells. Two-way ANOVA and Tukey's post-hoc
test.
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Fig. 7. Modiication of the HSCs niche – efect on tumour
cell homing. (A) Experimental outline of the in vivo study.
12-week old female BALB/c nude mice were injected daily
for 5 days with PBS or AMD3100 (5mg/kg i.p.) (n=5/
group). On day 5, animals were injected with 1× 105
Vybrant-DiD labelled MDA-MB-231-GFP-IV cells i.v. and
culled on day 10, tibias were collected for two-photon mi-
croscopy. (B) Ex vivo colony formation by HSC/PCs present
in the peripheral blood of 12-week old female BALB/c-Nude
mice treated daily for ive days with AMD3100 (5mg/Kg,
i.p.) or saline. Graph shows HSC/PCs colony numbers after
11 days of culture ex vivo. (*p<0.05 Mann-Whitney U test;
n=4/group). (C) Graph representing the homing of MDA-
MB-231-GFP-IV cells after treatment with the CXCR4 an-
tagonist AMD3100 (n=9 bones analysed) or with PBS
(n=10 bones analysed). Signiicantly greater number of
tumour cells was detected in ROI1 after the mobilization of
the HSCs cells outside the niche. *p≤0.05 two-way ANOVA
and Tukey's post-hoc test.
Fig. 8. Disseminated breast cancer cells
reside in perivascular locations within
mouse long bones. Immunoluorescent
labelling of tibial cryosections from
young and mature mice containing
human MDA-MB-231 breast cancer cells
with antibodies against the vascular
marker Endomucin, the bone marker
Osteopontin and two human antigens
expressed by MDA-MB-231 cells. The
samples were prepared 6 days after
intra-cardiac injection of tumour cells
(scale bar= 50 µm). (For interpretation
of the references to color in this igure,
the reader is referred to the web version
of this article.)
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with numerous studies using xenograft models of bone metastasis
showing that only a limited number of tumour colonies (generally 1–5)
develop in individual bones following injection of ∼105 tumour cells.
As in human disease, the data from in vivo models (including the current
study) demonstrate that simply arriving in bone is not suicient to
cause the secondary tumour [3,5,6,35]. Malignant cells must be able to
interact with the microenvironment in order to receive and respond to
signals that control their survival and proliferation [36,37]. We have
carried out the irst detailed mapping of the tumour cells to establish
whether they locate close to the endosteal niche (nearest bone surface)
or whether they locate close to other tumour cells. Our data show that
individual tumour cells do not locate closely together, suggesting that
cells that have successfully found a suitable niche do not signal to other
tumour cells to home to the same space. This could suggest that there is
a limited number of available niches that could be saturated, meaning
that there is competition for the metastatic niches in bone, although this
needs to be further investigated. In all cases, tumour cells were found
closer to the nearest bone surface than to other tumour cells, suggesting
that cells preferentially home to endosteal niches.
Most studies using murine bone metastasis models are carried out in
young (∼6-week old) animals with high levels of bone remodelling, in
order to maximise tumour development and allow measurement of
therapeutic efects. In contrast, we have shown that when tumour cells
are injected into animals with a more mature skeleton (>12-week old),
only around 20% of the mice will develop overt tumour growth in bone.
In the remaining 80%, the tumour cells home to bone but remain
dormant in the absence of accelerated bone turnover [30]. Several
studies, including from our own laboratory, have shown that sub-
sequent alteration of the bone microenvironment to accelerate bone
turnover such as OVX [38] or castration [39] triggers the growth of the
disseminated tumour cells to form bone metastases. These studies
highlight the major diferences between tumour growth in young
compared to mature mice, but is this due to the ageing bone micro-
environment having reduced capacity to support tumour growth, or
could it also be due to increased numbers of tumour cells reaching bone
in the young animals? We answered this question by injecting young
and mature animals with the same number of breast cancer cells and
quantifying their abundance and location 5 days later. There were no
signiicant diferences in the early steps of the breast cancer dis-
semination to bone between young and mature animals, neither in the
number of cells homing to bone nor in their location within the bone
microenvironment. These results support the hypothesis that the dif-
ferences in subsequent tumour outgrowth are due to tumour cells re-
ceiving signals from the microenvironment, rather than to diferences
in how and where the tumour cells reach the metastatic niches in young
and mature animals. These results are in agreement with our earlier
study using DiD-labelled MDA-MB-231 or PC3 prostate cancer cells
injected in 6- and 16-week old mice via the intra-cardiac route, re-
sulting in comparable numbers of tumour cells located in the long bones
of animals of both ages 7 days after injection [30]. Taken together,
these studies provide evidence that tumour cells locate to bone marrow
niches with the same frequency in young and mature animals, despite
the considerable diferences between the bone microenvironments.
The trabecular areas of mouse long bones contain a complex and
extensive microvascular network, recently reported to consist of dis-
tinct vessel subtypes (termed H and L vessels) with potential diferential
function [22]. H vessels located in the metaphysis form a novel,
structurally distinct capillary subtype, shown to mediate microvascular
growth and maintenance of perivascular osteoprogenitors, thereby
coupling angiogenesis and osteogenesis. We found that the majority of
tumour cells were located in the region of trabecular bone (RO1) that
contains H vessels, suggesting that there could be interactions between
disseminated tumour cells and this speciic vessel type, although this
warrants further investigation. As two-photon microscopy is not suited
to visualise multiple cell types in the same sample, we used confocal
microscopy to determine whether MDA-MB-231 breast cancer cells
located to sites in close proximity to endothelial cells. We found that 6
days after injection, breast cancer cells were situated in perivascular
sites in the trabecular areas of bone, consistent with the hypothesis that
the endosteal and perivascular niche areas broadly overlap in this re-
gion. Studies using ex-vivo models have reported that the micro-
vasculature regulates the quiescent state of breast cancer cells, and that
expression of thrombospondin (TSP-1) by the stable microvasculature
supports dormancy whereas pro-tumourigenic molecules (like periostin
and TGF-b1) produced during vessel sprouting stimulates tumour cell
proliferation [26]. We were unable to determine whether tumour cells
were more closely associated with osteoblastic cells compared to cells
of the microvasculature, both being highly abundant in the area of bone
where tumour cells wer located. We could therefore not establish
whether either of these cell types are likely to provide more dominant
regulation of tumour cell dormancy/proliferation in this model system,
as soluble factors released locally would reach the tumour cells re-
gardless of whether the source was the microvasculature or the bone
cells. However, as shown in Fig. 8, 6 days after injection, tumour cells
were found located immediately adjacent to endothelial cells and ap-
peared to wrap around the outer surface of the vessels, supporting a
potential direct interaction between tumour cells and endothelial cells.
A major criticism of murine breast cancer bone metastasis models is
the almost exclusive use of ER-ve tumour cells, despite the majority of
patients developing bone metastases having ER+ve disease [40]. The
lack of representative ER+ve models is mainly due to the need for
animals to receive oestrogen supplementation for tumours to develop,
although ER+ve mouse mammary tumour cell lines have been devel-
oped that form colonies in bone independently of oestrogen in im-
munocompetent mice [41]. We have previously shown that oestrogen
has a major impact on the bone microenvironment, its potent bone
anabolic efects altering the biology of the niche, precluding studies of
bone metastasis [42]. However, here we hypothesised that the early
homing steps and survival of ER+ve tumour cells for the irst few days
in bone are hormone-independent and can be studied in the absence of
oestrogen supplementation. Comparing the homing of diferent breast
cancer cell lines to bone, we found that the preferred location of ER+ve
tumour cells in bone was comparable to that of ER-ve cells, although
some minor diferences between the diferent cell lines were observed.
Our data provide valuable new information to show that the early steps
of tumour cell dissemination in bone is not dependent on ER status of
the tumour cells or require oestrogen supplementation to be successful,
opening the ield for further studies of the mechanisms regulating in-
itiation of bone metastasis in ER+ve breast cancer.
Breast cancer cells home to the same areas of bone that harbour the
HSC niche, and using prostate cancer models Shiozawa and colleagues
demonstrated that mobilisation HSCs caused by administration of the
CXCR4 antagonist AMD3100 in vivo increased the number of prostate
cancer able to seed in the bone [20,21]. They concluded that prostate
cancer cells located to HSC niches, however whether this also applies to
breast cancer cells has, to our knowledge, not been investigated. As the
MDA-MB-231-IV cells used in our study do not express CXCR4, possibly
due to the cycles of in vivo selection to make them home to bone,
AMD3100 could not be used to mobilise them from the bone marrow
into the circulation. We therefore used two-photon microscopy to es-
tablish mobilisation of HSCs prior to tumour cell injection resulted in
alterations in the location and/or number of breast cancer cells within
bone. We provide the irst demonstration that, in agreement with re-
ports from prostate cancer models, modiication of the HSCs population
resulted in alteration of the overall number of ER-ve breast cancer cells
detected in the bone microenvironment. Our data support that breast
cancer cells locate to HSCs niches within bone and that mobilisation of
HSCs appears to free up space for tumour cells to colonise, thereby
potentially increasing the risk of developing bone metastases. Our data
provide strong evidence to support that breast cancer cells locate to
similar locations within the long bones irrespective of their ER status,
hence likely colonise the same niches, although further studies would
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be needed to conclusively show that ER+ve breast cancer cells home to
HSC niches. It is possible that administration of AMD3100 could in-
luence bone-resident cell types other than HSC/progenitor cells.
However, signiicant efects on bone turnover have only been reported
after prolonged treatment with AMD3100. Im et al. reported that
AMD3100 treatment (5mg/kg/day) for 21 consecutive days induced
release of SDF-1, preventing ovariectomy-induced bone loss in female
C57BL/6 mice by decreasing the number of osteoclasts diferentiated
from BM-derived precursors [43]. In contrast, short term administration
of 5mg/kg/day AMD3100 to C57BL/6 mice for 3 days is reported not
to afect bone mineral density in vivo [44]. Using a prostate cancer
model, Zalucha et al. reported that male SCID mice administered
AMD3100 (5mg/kg daily for 5 days) had increased number of osteo-
clasts compared to control accompanied by a trend towards increased
seeding of subsequently injected prostate cancer cells in the bone
marrow [45].
Taken together, this study provides valuable new information about
how in vivo models of breast cancer bone metastasis can be combined
with advanced imaging to establish the early steps of tumour cell co-
lonisation of bone. We demonstrate that both ER+ve and ER-ve breast
tumour cells homing to long bones is microenvironment dependent,
with cells locating to highly vascularised, trabecular areas in both
young and mature animals. We also show that the homing pattern is
unafected by the cellular dye used to label the tumour cells and by the
route of administration, supporting that studies using diferent meth-
odologies could be broadly comparable. Finally, we provide evidence
that breast cancer cells home to the HSC niche, supporting that the HSC,
perivascular, endosteal and metastatic niche are overlapping in this
model system.
5. Conclusions
Our indings demonstrate that in mouse models of bone metastasis,
breast cancer cells home to speciic bone sites irrespective of their ER
status, the age of the recipient animal or the injection route, supporting
that tumour cells home to niche areas where the bone microenviron-
ment is supportive of their colonisation and survival. Tumour cells lo-
cate closer to the nearest bone surface than to other tumour cells,
suggesting that the environment, not the presence of other cancer cells,
supports tumour cell homing by providing suitable niches. Mobilisation
of HSC resulted in increased numbers of tumour cells homing to bone,
supporting that the metastatic niche and the HSC niche are overlapping.
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